Provided is use of a pharmaceutical composition in treating a glucocorticoid-resistant tumor characterized by an increased level of Akt2 expression. The pharmaceutical composition comprises an Akt2 inhibitor, a glucocorticoid, and optionally a pharmaceutically acceptable carrier, excipient and/or diluent. Also provided are use of an Akt2 detecting agent in detecting a glucocorticoid-resistant tumor, and use of an Akt2 inhibitor in the preparation of a pharmaceutical composition for treating a tumor.